© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 1, 48-53,
January 5, 2000
© 2000 Oxford University Press
REPORTS |
Estimation of Tamoxifen's Efficacy for Preventing the Formation and Growth of Breast Tumors
Affiliation of authors: Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Correspondence to: Michael D. Radmacher, Ph.D., National Institutes of Health, 7550 Wisconsin Ave., MS 9015, Bethesda, MD 20892-9015 (e-mail: mdradmac{at}helix.nih.gov).
BACKGROUND: Several randomized clinical trials have tested the hypothesis that tamoxifen is effective in preventing breast cancer. The largest such trial, the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial (BCPT), reported a 49% reduction in risk of invasive breast cancer for the tamoxifen group. However, it is unclear whether the effect of tamoxifen in this trial was mainly due to prevention of newly forming tumors or to treatment of occult disease. METHODS: We used various tumor growth models (i.e., exponential and Gompertzian [growth limited by tumor size]) and a computer simulation to approximate the percentage of detected tumors that were initiated after study entry. Maximum likelihood techniques were then used to estimate separately the efficacy of tamoxifen in treating occult disease and in preventing the formation and growth of new tumors. RESULTS: Under the assumptions of most of the growth models, the trial was sufficiently long for substantial numbers of new tumors to form, grow, and be detected during the trial. With the Gompertzian model and all available incidence data from the BCPT, it was estimated that 60% (95% confidence interval [CI] = 40%-80%) fewer new tumors were detected in the tamoxifen group than in the placebo group. Likewise, 35% (95% CI = 6%-63%) fewer occult tumors were detected in the tamoxifen group. With this model, the estimated incidence rate of invasive breast cancer among women in the placebo group of the BCPT was 7.7 (95% CI = 6.6-8.9) per 1000 women per year. Similar results were obtained with three exponential tumor growth models. CONCLUSIONS: These results support the concept that tamoxifen reduced cancer incidence in the BCPT through both treatment of occult disease and prevention of new tumor formation and growth. However, data from prevention trials may never be sufficient to completely distinguish prevention of new tumor formation from treatment of occult disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Shen, J. P. Costantino, and J. Qin Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast Cancer J Natl Cancer Inst, October 7, 2008; (2008) djn320v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman and J. V. Heymach The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention Clin. Cancer Res., July 15, 2007; 13(14): 4035 - 4041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zheng, A. Kallio, and P. Harkonen Tamoxifen-Induced Rapid Death of MCF-7 Breast Cancer Cells Is Mediated via Extracellularly Signal-Regulated Kinase Signaling and Can Be Abrogated by Estrogen Endocrinology, June 1, 2007; 148(6): 2764 - 2777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. T. Gaddy, J. T. Barrett, J. N. Delk, A. M. Kallab, A. G. Porter, and P. V. Schoenlein Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer Cells Clin. Cancer Res., August 1, 2004; 10(15): 5215 - 5225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lu, S. K. Mohsin, S. Hilsenbeck, A. Wakeling, and P. H. Brown RESPONSE: Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors J Natl Cancer Inst, May 5, 2004; 96(9): 715 - 716. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Kinsinger, R. Harris, S. H. Woolf, H. C. Sox, and K. N. Lohr Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 2, 2002; 137(1): 59 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and W. Ki Hong Cancer Prevention by Delay : Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. Clin. Cancer Res., February 1, 2002; 8(2): 305 - 313. [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan, S. Gapstur, and M. Morrow Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mandlekar, V. Hebbar, K. Christov, and A-N. T. Kong Pharmacodynamics of Tamoxifen and Its 4-Hydroxy and N-Desmethyl Metabolites: Activation of Caspases and Induction of Apoptosis in Rat Mammary Tumors and in Human Breast Cancer Cell Lines Cancer Res., December 1, 2000; 60(23): 6601 - 6606. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. B. Muchmore Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects Oncologist, October 1, 2000; 5(5): 388 - 392. [Abstract] [Full Text]
|
|
|
|
|
|
S. Menard, E. Tagliabue, M. Campiglio, and A. Balsari Re: Estimation of Tamoxifen's Efficacy for Preventing the Formation and Growth of Breast Tumors J Natl Cancer Inst, June 7, 2000; 92(11): 943a - 943a. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Radmacher and R. Simon RESPONSE: Re: Estimation of Tamoxifen's Efficacy for Preventing the Formation and Growth of Breast Tumors J Natl Cancer Inst, June 7, 2000; 92(11): 943b - 944b. [Full Text] [PDF]
|
|